This is great now that we have a an official Journal report, but the next problem is, who’s going to pay for the test? Clinical Trials will certainly stand to help out here. We recently had this report that said it is not cost effective all the time.
So it appears we are back to risk management here once again governing science R and D and clinical use in this area, but hopefully the trials will prove successful so time will determine the winner, tests or risk management saying no. BD
NEW YORK (GenomeWeb News) – Combining genetic and clinical information can significantly improve warfarin dose predictions for individuals who need high or low doses of the drug, according to a paper appearing in today's issue of the New England Journal of Medicine.
Coming on the heels of these results, the National Institutes of Health in the US and universities in the UK announced that they are planning clinical trials to determine whether incorporating genetics into warfarin dosing will improve patient outcome.
To address this issue, the NIH, which helped support the latest study, is planning to launch a large prospective, multi-center, randomized clinical trial in the US next month. The "Clarification of Optimal Anticoagulation through Genetics" will enroll 1,200 participants at a dozen clinical sites.